scholarly journals Risk of Venous Thromboembolism Following Hemorrhagic Fever With Renal Syndrome: A Self-controlled Case Series Study

2017 ◽  
Vol 66 (2) ◽  
pp. 268-273 ◽  
Author(s):  
Anne-Marie Connolly-Andersen ◽  
Heather Whitaker ◽  
Jonas Klingström ◽  
Clas Ahlm
Keyword(s):  
Venous Thromboembolism ◽  
Case Series ◽  
Hemorrhagic Fever ◽  
Case Series Study ◽  
Series Study

A Five-Member Family With Crimean-Congo Hemorrhagic Fever; A Case Series Study

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Mohammad Rakhshani ◽  
Fatemeh Abedi-poor ◽  
Masoume Noori-Jangi ◽  
Parisa Khoorgami ◽  
Ali Hajalizadeh ◽  
...  
Keyword(s):  
Case Series ◽  
Hemorrhagic Fever ◽  
Crimean Congo Hemorrhagic Fever ◽  
Case Series Study ◽  
Series Study

scholarly journals Clinical Features of Venous Thromboembolism in Patients With Coronavirus Disease 2019 (COVID-19) in Japan　― A Case Series Study ―

2021 ◽  
Vol 85 (3) ◽  
pp. 309-313
Author(s):  
Yugo Yamashita ◽  
Nobuhiro Hara ◽  
Masahiro Obana ◽  
Satoshi Ikeda ◽  
Motohiko Furuichi ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Clinical Features ◽  
Case Series ◽  
Case Series Study ◽  
Series Study

scholarly journals Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

BMJ ◽  
2021 ◽  
pp. n1931 ◽  
Author(s):  
Julia Hippisley-Cox ◽  
Martina Patone ◽  
Xue W Mei ◽  
Defne Saatci ◽  
Sharon Dixon ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Hospital Admission ◽  
Ischaemic Stroke ◽  
Case Series ◽  
Positive Test ◽  
Vascular Events ◽  
Arterial Thromboembolism ◽  
Case Series Study ◽  
Increased Risk ◽  
Series Study

Abstract Objective To assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults. Design Self-controlled case series study using national data on covid-19 vaccination and hospital admissions. Setting Patient level data were obtained for approximately 30 million people vaccinated in England between 1 December 2020 and 24 April 2021. Electronic health records were linked with death data from the Office for National Statistics, SARS-CoV-2 positive test data, and hospital admission data from the United Kingdom’s health service (NHS). Participants 29 121 633 people were vaccinated with first doses (19 608 008 with Oxford-AstraZeneca (ChAdOx1 nCoV-19) and 9 513 625 with Pfizer-BioNTech (BNT162b2 mRNA)) and 1 758 095 people had a positive SARS-CoV-2 test. People aged ≥16 years who had first doses of the ChAdOx1 nCoV-19 or BNT162b2 mRNA vaccines and any outcome of interest were included in the study. Main outcome measures The primary outcomes were hospital admission or death associated with thrombocytopenia, venous thromboembolism, and arterial thromboembolism within 28 days of three exposures: first dose of the ChAdOx1 nCoV-19 vaccine; first dose of the BNT162b2 mRNA vaccine; and a SARS-CoV-2 positive test. Secondary outcomes were subsets of the primary outcomes: cerebral venous sinus thrombosis (CVST), ischaemic stroke, myocardial infarction, and other rare arterial thrombotic events. Results The study found increased risk of thrombocytopenia after ChAdOx1 nCoV-19 vaccination (incidence rate ratio 1.33, 95% confidence interval 1.19 to 1.47 at 8-14 days) and after a positive SARS-CoV-2 test (5.27, 4.34 to 6.40 at 8-14 days); increased risk of venous thromboembolism after ChAdOx1 nCoV-19 vaccination (1.10, 1.02 to 1.18 at 8-14 days) and after SARS-CoV-2 infection (13.86, 12.76 to 15.05 at 8-14 days); and increased risk of arterial thromboembolism after BNT162b2 mRNA vaccination (1.06, 1.01 to 1.10 at 15-21 days) and after SARS-CoV-2 infection (2.02, 1.82 to 2.24 at 15-21 days). Secondary analyses found increased risk of CVST after ChAdOx1 nCoV-19 vaccination (4.01, 2.08 to 7.71 at 8-14 days), after BNT162b2 mRNA vaccination (3.58, 1.39 to 9.27 at 15-21 days), and after a positive SARS-CoV-2 test; increased risk of ischaemic stroke after BNT162b2 mRNA vaccination (1.12, 1.04 to 1.20 at 15-21 days) and after a positive SARS-CoV-2 test; and increased risk of other rare arterial thrombotic events after ChAdOx1 nCoV-19 vaccination (1.21, 1.02 to 1.43 at 8-14 days) and after a positive SARS-CoV-2 test. Conclusion Increased risks of haematological and vascular events that led to hospital admission or death were observed for short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of most of these events were substantially higher and more prolonged after SARS-CoV-2 infection than after vaccination in the same population.

Evaluating Vitality and Periodontal Sensitivity of Teeth Adjacent to the Site of Open Sinus Lift Surgery before and after Treatment: A Case Series Study

2020 ◽  
Vol 30 (2) ◽  
pp. 77-81
Author(s):  
Amir Moeintaghavi ◽  
Negar Azami ◽  
Mohammad Sadegh Zohrevand ◽  
Farid Shiezadeh ◽  
Hamid Jafarzadeh ◽  
...  
Keyword(s):  
Case Series ◽  
Sinus Lift ◽  
Case Series Study ◽  
Before And After ◽  
Series Study

Perfil microbiológico en los pacientes con diagnóstico de sinusitis nosocomial hospitalizados en la Unidad de Cuidados Intensivos del Hospital de San José durante el período de Febrero de 2013 a Marzo de 2015. Microbiological profile in patients diagnosed with nosocomial sinusitis hospitalized in the Intensive Care Unit of the Hospital of San Jose during the period February 2013 to March 2015.

2018 ◽  
Vol 45 (4) ◽  
pp. 261-266
Author(s):  
Jorge Luis Alfredo Herrera Ariza ◽  
Mario Alejandro Villabón ◽  
Ángela Carolina Rojas Ruiz ◽  
Iván Fernando Moncada
Keyword(s):  
Disease Control ◽  
Maxillary Sinus ◽  
Case Series ◽  
San Jose ◽  
Study Materials ◽  
Case Series Study ◽  
Nosocomial Sinusitis ◽  
Centers For Disease Control ◽  
Microbial Agents ◽  
Series Study

Objetivo: Determinar los agentes microbianos más frecuentes en pacientes de UCI con diagnóstico de sinusitis nosocomial en el Hospital de San José, período de dos años. Diseño: Estudio observacional tipo serie de casos. Materiales y métodos: Se incluyeron pacientes mayores de 18 años con una estancia hospitalaria mayor a 48 horas, que desarrollaron sinusitis nosocomial de acuerdo a los criterios de los Centers for Disease Control (CDC). Uso de dos técnicas: punción y lavado de seno maxilar. Resultados: 19 pacientes que cumplen los criterios de sinusitis nosocomial. Edad promedio 55 años, predominio sexo masculino. El 94.7% tuvo sonda orogástrica, 89.5% intubación orotraqueal y 89.5% ventilación mecánica. Hubo aislamiento polimicrobiano de gram positivos, gram negativos, anaerobios y hongos. La mortalidad en UCI fue 32%. Conclusiones: Se presenta una adecuada sensibilidad al tratamiento con vancomicina y piperacilina tazobactam en esta patología. El rendimiento diagnóstico es igual al realizar lavado y punción del seno maxilar.Objetive: To determine the microbial agents on UCI patients who have beendiagnosed with nosocomial sinusitis at the San Jose Hospital, (Bogota, Colombia) in a two-year period. Design: Case series study. Materials and methods: Patients who were older than 18-year olds, with a hospitalization longer than 48 hours who developed nosocomial sinusitis, according to the criteria established by the Centers for Disease Control (CDC) were included. Two techniques were employed for data collection: puncture and maxillary sinus wash. Results: 19 patients fulfill the criteria requirements for nosocomial sinusitis. Average age was 55 years old. Population mostly was composed by male individuals. 94.7% had a gastric tube intervention; 89.5% had tracheal intubation 89.5% mechanical ventilation. Polymicrobial isolation with gram positive, gram negative, anaerobic and fungi were identified. Mortality in critical care unites was 32%. Conclusions: An adequate sensitivity to treatment with vancomycin and piperacillin tazobactam was evidenced in this pathology.To perform a washing or maxillary sinus puncture had the same efficiency fordiagnosing this disease.

The case for skin camouflage in the management of upper limb scarring – A case series

Hand Therapy ◽  
2021 ◽  
pp. 175899832110078
Author(s):  
Laura Adamson ◽  
Anna Selby
Keyword(s):  
Upper Limb ◽  
Case Series ◽  
Primary Objective ◽  
Self Confidence ◽  
Published Evidence ◽  
Case Series Study ◽  
Visual Impact ◽  
Series Study ◽  
Increasing Function

Introduction For some people the appearance of their hands is as important as function. Upper limb scarring can cause some patients distress. Skin camouflage is an intervention that can be used to reduce the visual impact of a scar but there is limited published evidence for its use for hand scarring. Methods This is a case series study with a primary objective to determine whether skin camouflage reduces distress in patients with an upper limb scar and to evaluate this new service. Patients experiencing distress from an upper limb scar were recruited from a hand therapy outpatient clinic. The intervention delivered was a one hour skin camouflage session. Photographs of the upper limb pre and post skin camouflage intervention were taken. The patient-rated Michigan Hand Questionnaire (MHQ) and Derriford Appearance Scale (DAS24) were completed before treatment, at 1 week and 1 month after treatment. Results Six participants reporting distress from an upper limb scar received skin camouflage intervention. Only three out of six participants completed all follow-up. All three showed improvement in at least two domains of the MHQ (function and aesthetics) at one month post treatment. Increased confidence during functional and work-based activities was also reported on the DAS24. Participants reported increased engagement in daily activities as a result of being able to camouflage their scars. Conclusions This small case series shows that skin camouflage intervention may be beneficial for some patients who are experiencing distress related to an upper limb scar by increasing function and self-confidence.

Sign in / Sign up

Export Citation Format

Share Document